Media Summary: CETSA® - What, Why and When in One Minute Presentation by Michael Dabrowski, PhD, CEO of Pelago Bioscience held at the Virtual CHI Drug Discovery meeting (August ... Do you use biologically relevant assays to understand compound selectivity? Assessing the selectivity of candidate drugs is ...
Cetsa What Why And When - Detailed Analysis & Overview
CETSA® - What, Why and When in One Minute Presentation by Michael Dabrowski, PhD, CEO of Pelago Bioscience held at the Virtual CHI Drug Discovery meeting (August ... Do you use biologically relevant assays to understand compound selectivity? Assessing the selectivity of candidate drugs is ... Target deconvolution after phenotypic screening can be an extremely challenging task. And we have a solution for that: Presentation by Stina Lundgren, PhD, Principal Project Advisor at Pelago Bioscience held at the Virtual CHI Drug Discovery ... In this webinar, you will find the details of the study where
Bridging the Gap Between In Vitro and In Vivo Drug Discovery Translating early-stage drug discovery into clinical success is one ... Characterising cellular target engagement of ERAP1 & 2 using Pelago Bioscience is bringing together the Launch of CDK2 and CDK4 Alpha SureFire® CETSA® Target Engagement Assay Kit Join this Pelago Bioscience webinar to learn more about Dartmouth SYNERGY is funded by the NIH's Clinical and Translational Science Award program. This CTSA grant totals $18 ...
The HECAT is a set of guidance documents, appraisal tools, and resources to conduct a thorough and consistent analysis of ...
